Chemours Company (NYSE:CC) has a beta value of 1.59 and has seen 2.83 million shares traded in the last trading session. The company, currently valued at $1.97B, closed the last trade at $13.17 per share which meant it lost -$0.32 on the day or -2.37% during that session. The CC stock price is -93.93% off its 52-week high price of $25.54 and 30.68% above the 52-week low of $9.13. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.71 million shares traded. The 3-month trading volume is 4.23 million shares.
The consensus among analysts is that Chemours Company (CC) is Buy stock at the moment, with a recommendation rating of 2.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 13 have rated it as a Hold, with 10 advising it as a Buy. 1 have rated the stock as Underweight. The expected earnings per share for the stock is 0.48.
Chemours Company (NYSE:CC) trade information
Sporting -2.37% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the CC stock price touched $13.17 or saw a rise of 10.95%. Year-to-date, Chemours Company shares have moved -45.71%, while the 5-day performance has seen it change -3.37%. Over the past 30 days, the shares of Chemours Company (NYSE:CC) have changed 14.82%. Short interest in the company has seen 14.33 million shares shorted with days to cover at 3.53.
Wall Street analysts have a consensus price target for the stock at $16, which means that the shares’ value could jump 17.69% from current levels. The projected low price target is $15.0 while the price target rests at a high of $17.0. In that case, then, we find that the current price level is -29.08% off the targeted high while a plunge would see the stock gain -13.9% from current levels.
Chemours Company (CC) estimates and forecasts
The company’s shares have lost -25.34% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 2.57%.
5 analysts offering their estimates for the company have set an average revenue estimate of 1.58B for the current quarter. 5 have an estimated revenue figure of 1.57B for the next ending quarter. Year-ago sales stood 1.54B and 1.5B respectively for this quarter and the next, and analysts expect sales will grow by 2.94% for the current quarter and 2.57% for the next.
Earnings growth for 2025 is a modest 23.10% while over the next 5 years, the company’s earnings are expected to increase by 31.24%.
CC Dividends
Chemours Company is expected to release its next earnings report on 2025-May-06 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue. The forward dividend is 0.84 at a share yield of 6.36%. The company’s dividend yield has gone up over the past 12 months, with a 5 Year Average Dividend Yield of 4.05%.
Chemours Company (NYSE:CC)’s Major holders
Insiders own 0.46% of the company shares, while shares held by institutions stand at 97.81% with a share float percentage of 98.27%. Investors are also buoyed by the number of investors in a company, with Chemours Company having a total of 539.0 institutions that hold shares in the company. The top two institutional holders are FMR LLC with over 17.52 million shares worth more than $395.51 million. As of 2024-06-30, FMR LLC held 11.7284% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 16.26 million shares as of 2024-06-30. The firm’s total holdings are worth over $366.98 million and represent 10.8823% of shares outstanding.
